Health
STAT+: Peptide market poised to explode with new Hims and Noom launches
Publication: STAT
Author: Sarah Todd and Katie Palmer
Source published: 19/11/2026, 16:59:47 UTC
Briefing created: 19/11/2026, 18:14:04 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 19/11/2026, 17:51:24 UTC.
Briefings
Telehealth companies Hims and Noom announced the launch of prescription peptides for eligible patients, marking a pivotal moment for the synthetic peptide market in the United States. These companies are among the industry's dominant players, with Hims holding a market cap exceeding $3.5 billion and Noom valued at $3.7 billion. While peptides are short-chain amino acids initially popular among bodybuilders, many marketed drugs remain experimental and lack FDA approval or human safety trials. The announcement highlights the potential for peptides to go mainstream, though the specific benefits and regulatory status remain uncertain.
Key points
- Telehealth companies Hims and Noom announced the launch of prescription peptides for eligible patients, marking a pivotal moment for the synthetic peptide market in the United States.
- Hims holds a market cap exceeding $3.5 billion while Noom is valued at $3.7 billion, making their announcements significant for the industry.
Context
Peptides are short-chain amino acids initially popular among bodybuilders but many marketed drugs remain experimental without FDA approval or human safety trials. The announcement highlights the potential for peptides to go mainstream, though the specific benefits and regulatory status remain uncertain.
Limitations
Evidence is limited to the announcement of new prescriptions by Hims and Noom. Specific benefits, regulatory approvals, and safety data for these peptides are not provided. The article does not specify the exact number of eligible patients or the timeframe of the launch beyond the current date.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/11/2026, 18:14:04 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeicu65vsymyzrwpalqqkqu2fcj5kigwplg3bzorialfyzofrldmzqi